Aster DM Quality Care
Market cap ₹63,646 Cr
- P/E
- 93.00
- Day range
- ₹728.00 – ₹750.60
- 52-week range
- ₹519.10 – ₹891.30
- Volume
- 8.66 L
- Open
- ₹739.40
- Prev close
- ₹737.95
Latest results · Q2 FY27(consolidated)Revenue ₹2,829 Cr+136.3%Profit ₹322 Cr+165.7%Margin 11.4%YoY vs the same quarter last year
1 red flag to read up on
- high
Promoter pledge went up
66.99% of promoter shares pledged, up from 18.17% · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
ASTERDM in NSE indices and F&O
Research profile
Composite 50 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.1%
- Graham no.
- ₹110.70
- vs Graham
- -84.9%
- ROE ÷ P/B
- 1.5%
- 12-1 mom.
- -1.1%
- Return / vol
- 0.25
- Magic Formula
- #557
- Piotroski
- 4/6
- FCF yield
- 0.3%
Appears in 10 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Aster DM Quality CareASTERDM | ₹63,646 Cr | 93.00 | 8.08 | 11.8% | 12.0% | 23.0% | 0.76 | +136.3% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 9h agoHeadlines about Aster DM Quality Care from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 122.0
- Price / Book
- 8.18
- ROE (FY26)
- 11.8%
- ROCE (latest year)
- 12%
- Dividend yield
- 0.41%
Moving averages (NSE)
- 20-day
- ₹696.59
- Price above
- 50-day
- ₹715.93
- Price above
- 200-day
- ₹721.52
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 | 1,186 | 1,182 | 1,311 | 2,829 |
| YoY Sales growth | -70 | — | — | — | — | — | — | — | — | — | — | — |
| Expenses | 805 | 817 | 841 | 869 | 864 | 818 | 876 | 961 | 983 | 958 | 1,055 | 2,174 |
| Operating Profit | 149 | 156 | 161 | 217 | 186 | 182 | 202 | 236 | 202 | 224 | 256 | 655 |
| OPM % | 16% | 16% | 16% | 20% | 18% | 18% | 19% | 20% | 17% | 19% | 20% | 23% |
| Other Income | 153 | -40 | 5,120 | 35 | 9 | 5 | 29 | 28 | 0 | 37 | -77 | 33 |
| Interest | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 | 31 | 30 | 31 | 119 |
| Depreciation | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 | 68 | 67 | 69 | 150 |
| Profit before tax | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 | 167 | 103 | 163 | 78 | 419 |
| Tax % | 5% | 108% | 1% | 33% | 37% | 6% | 31% | 27% | 43% | 6% | 62% | 23% |
| Net Profit | 209 | -2 | 5,152 | 106 | 64 | 86 | 94 | 121 | 59 | 154 | 29 | 322 |
| EPS in Rs | ₹3.59 | ₹-0.48 | ₹103.00 | ₹1.94 | ₹1.14 | ₹1.58 | ₹1.65 | ₹2.12 | ₹1.01 | ₹2.71 | ₹0.31 | ₹3.01 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-62 days since Mar 2021
-90 days since Mar 2021
-122 days since Mar 2021
-29 days since Mar 2021
-33 days since Mar 2021
Strengths, risks & growth
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare. [1]
Strengths
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 1,560%
- Promoter holding has increased by 13.4% over last quarter.
Risks
- Stock is trading at 8.18 times its book value
- Company has a low return on equity of 8.46% over last 3 years.
- Company might be capitalizing the interest cost
- Promoters have pledged 67.0% of their holding.
Compounded Sales Growth
- 10 Years
- -1%
- 5 Years
- -12%
- 3 Years
- +16%
- TTM
- +50%
Compounded Profit Growth
- 10 Years
- +48%
- 5 Years
- +23%
- 3 Years
- -1%
- TTM
- +43%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- +30%
- 3 Years
- +29%
- 1 Year
- +10%
Return on Equity
- 10 Years
- +9%
- 5 Years
- +10%
- 3 Years
- +8%
- Last Year
- +11%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 40.39% | 40.39% | 40.39% | 53.78% | +13.39 pp |
| FII | 18.46% | 17.18% | 10.53% | 12.26% | +1.73 pp |
| DII | 26.12% | 27.57% | 27.65% | 21.66% | -5.99 pp |
| Public | 14.80% | 14.61% | 21.41% | 12.17% | -9.24 pp |
| Others | 0.23% | 0.23% | 0.00% | 0.11% | +0.11 pp |
Filed with NSE for Sept 2026: promoters 53.79%, public 46.10%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 20.79% (+4.86 pp)- Promoters53.9%
- Foreign institutions12.3%
- Mutual funds20.8%
- Insurance0.7%
- Other domestic institutions0.2%
- Retail1.8%
- Others10.3%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Small Cap Fund | 2.06% | 3.45% | -0.44 pp |
| Kotak Mid Cap Fund | 1.58% | 1.59% | +0.49 pp |
| HDFC Mid Cap Fund | 1.49% | 0.96% | +0.54 pp |
| HDFC Focused Fund | 1.40% | 3.44% | +3.44 pp |
| HDFC Flexi Cap Fund | 1.25% | 0.75% | +0.09 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Avg
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 29.3%
- Downside volatility
- 27.7%
- Worst 5% of days
- 2.8%
- Average of that tail
- 3.7%
- Max drawdown (1Y)
- 25.9%
- Below its peak
- 15.9%
Against the market
- Beta vs Nifty 50
- 0.41
- Correlation
- 0.19
- Relative strength (3M)
- -14.7%
- ATR (14)
- 3.4%
Return
- Return 1M
- +8.4%
- Return 3M
- -10.8%
- Return 6M
- -3.2%
- Return 1Y
- +7.2%
- vs 200-day average
- +1.3%
Momentum
- RSI (14)
- 56.5
- MACD histogram
- 7.01
- Stochastic %K
- 70.2
- ADX (14)
- 29.3
- +DI / −DI
- 21.6 / 9.8
- Money flow index
- 72.4
Participation
- Delivery (20d avg)
- 56.2%
- vs its 60-day baseline
- -1.8 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.3%
- 52-week position
- 58 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹178 Cr
- FCF yield
- 0.3%
- Cash conversion
- 1.54
- Accruals ratio
- -0.028
- Net debt
- ₹5,164 Cr
- Net debt / equity
- 0.66
- EV / sales
- 10.57
- Capex intensity
- 10.3%
- Revenue CAGR
- 99.9%
- Profit CAGR
- 142.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Union (Mauritius) Holdings Limited Promoter Group · Market Purchase | Buy | 91,174 | ₹6.9 Cr | 2 Sept 2026 |
Union (Mauritius) Holdings Limited Promoter Group · Market Purchase | Buy | 2,95,823 | ₹22.4 Cr | 2 Sept 2026 |
Union (Mauritius) Holdings Limited Promoter Group · Market Purchase | Buy | 46,09,800 | ₹350 Cr | 2 Sept 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹3.00
Interim Dividend - Rs 3 Per Share
2 Apr 2026ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
28 Aug 2025ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
10 Feb 2025ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
22 Aug 2024ex-date - dividend₹118.00
Special Dividend - Rs 118 Per Share
23 Apr 2024ex-date - buybackNot available — not reported in this filing
Buy Back
23 Jan 2020ex-date
Company announcements
Transcript of the 18th Annual General Meeting held on 28 September 2026 through Video Conferencing ("VC")
Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026
Submission of e-voting results along with scrutinizers report for the 18th AGM held on 28 September 2026
Retirement of Ms. Purana Housdurgam Vijayadeepti as Non- Executive Independent Director of the Company with effect from the conclusion of the 18th Annual General Meeting of the Company
Change in Directors of the Company
Summary of Proceedings of the 18th Annual General Meeting held on September 28, 2026 held at 11:30 A.M IST
Intimation of closure of Trading window
Disclosure of voting results of the Postal Ballot and submission of Scrutinizer's Report
Disclosure of voting results of the Postal Ballot and submission of Scrutinizer's Report
Please find enclosed an Addendum to the Notice of the 18th Annual General Meeting of the Company
Revision in Credit Rating of a Material Subsidiary
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on September ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Union (Mauritius) Holdings Ltd
Dispatch of Notice of 18th Annual General Meeting and Integrated Annual Report for the financial year 2025-26
Filed with BSE (scrip 540975); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Nov 2026Slides
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlides
- May 2026SlidesRecording
- Feb 2026TranscriptSlidesRecording
Credit ratings
- Rating update · 29 Jul from crisil
- Rating update · 3 Oct 2025 from icra
- Rating update · 16 Apr 2024 from icra
- Rating update · 7 Dec 2023 from icra
- Rating update · 20 Oct 2022 from icra
- Rating update · 9 Aug 2021 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 7 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Aster DM Quality Care: common questions
Answered from the figures on this page.